KannaLife: Difference between revisions
Content deleted Content added
mNo edit summary |
Tags: New redirect Reverted |
||
| Line 1: | Line 1: | ||
#REDIRECT [[Kannalife]] |
|||
{{Infobox company |
|||
|name = Kannalife Sciences Inc. |
|||
|logo = [[File:Kannalife-logo.jpg|250px|Corporate logo]] |
|||
|type = Private (Subsidiary) |
|||
|slogan = |
|||
|foundation = 2010 |
|||
|founders = Dean Petkanas, [[Thoma Kikis]] |
|||
|location = [[Doylestown, Pennsylvania]] |
|||
|area_served = |
|||
|industry = [[Pharmaceutical industry|Pharmaceutical]] |
|||
|revenue = |
|||
|net_income = |
|||
|assets = Exclusive License of patent {{patent|US|6630507}} |
|||
|equity = |
|||
|homepage = [http://kannalife.com/ http://kannalife.com] |
|||
}} |
|||
[[File:US-patent-6630507.pdf|thumb|right|KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent {{patent|US|6630507}} “Cannabinoids as Antioxidants and Neuroprotectants."]] |
|||
'''Kannalife Sciences Inc.''' , a subsidiary of [[Neuropathix|Neuropathix, Inc.]], is a bio-pharmaceutical and phyto-medical company based in [[Doylestown, Pennsylvania]] founded by Dean Petkanas and [[Thoma Kikis]].<ref>{{cite web |url=https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |archive-url=https://web.archive.org/web/20150508055419/https://news.vice.com/article/the-nfls-anti-weed-policy-even-extends-to-drugs-that-could-prevent-brain-damage |url-status=live |archive-date=May 8, 2015 |title=The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage |last=Guion |first=Payton |date=November 12, 2014 |work=VICE News |accessdate=2014-12-12 }}</ref> Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce [[oxidative stress]], and act as immuno-modulators and neuroprotectants.<ref name="nyt1">{{cite web|url=https://www.nytimes.com/2014/11/02/nyregion/a-competition-to-get-a-medical-marijuana-license-in-new-york.html?_r=0|title=For Pot Inc., the Rush to Cash In Is Underway|last=Leland|first=John|date=October 31, 2014|work=The New York Times|accessdate=2014-10-31}}</ref> |
|||
In 2011, the company was granted an Exclusive License<ref>{{cite web|url=https://www.federalregister.gov/articles/2011/11/17/2011-29726/prospective-grant-of-exclusive-license-development-of-cannabinoids-and-cannabidiols-based |title=Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. |publisher=federalregister.gov |date= |accessdate=2011-11-17}}</ref> by [[National Institutes of Health]] – Office of Technology Transfer ([[NIH Office of Technology Transfer|NIH-OTT]]) for the Commercialization of patent {{patent|US|6630507}}, “Cannabinoids as Antioxidants and Neuroprotectants."<ref>{{cite web|url=http://www.thestreet.com/story/11609018/1/kannalife-sciences-inc-signs-exclusive-license-agreement-with-national-institutes-of-health-office-of-technology-transfer-nih-ott.html |title=Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT) |publisher=thestreet.com |date= |accessdate=2012-07-09}}</ref> |
|||
Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/kannalife-in-r-amp-d-collaboration-for-cannabinoid-based-drugs/81248179/ |title=Kannalife in R&D Collaboration for Cannabinoid-Based Drugs |publisher=Genengnews.com |date= |accessdate=2013-04-04}}</ref> in Doylestown, PA, for a target drug candidate, KLS-13019<ref name=Kinney-2016>{{cite journal|author1=William A. Kinney |author2=Mark E. McDonnell |author3=Hua Marlon Zhong |author4=Chaomin Liu |author5=Lanyi Yang |author6=Wei Ling |author7=Tao Qian |author8=Yu Chen |author9=Zhijie Cai |author10=Dean Petkanas |author11=Douglas E. Brenneman |title=Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability|journal=ACS Med. Chem. Lett.|doi=10.1021/acsmedchemlett.6b00009|pmc=4834656 }}</ref> to treat [[Chemotherapy-induced peripheral neuropathy]], [[Hepatic encephalopathy]], [[Concussion|Mild Traumatic Brain Injury]] and [[Chronic traumatic encephalopathy|CTE]],<ref>{{cite web|url=http://www.foxnews.com/health/2014/11/10/medical-marijuana-company-developing-drug-to-protect-nfl-players-brains/ |title=Medical marijuana company developing drug to protect NFL players’ brains |last=Mulvihill Moran |first=Jessica |date=November 9, 2014 |work=Fox News |accessdate=2014-11-09}}</ref> an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain. |
|||
Kannalife was featured in [[Sports Illustrated]] article on using cannabinoids to treat [[Concussion|Concussions]] and [[chronic traumatic encephalopathy|CTE]]. <ref>{{cite web|url=http://www.si.com/nfl/2016/07/12/cannabis-cte-treatment-kannalife |title=How cannabis is helping one company research treatment of CTE |date=July 12, 2016|work=Sports Illustrated}}</ref> |
|||
==References== |
|||
{{Reflist}} |
|||
[[Category:Health care companies established in 2010]] |
|||
[[Category:Health care companies based in Pennsylvania]] |
|||
[[Category:Companies based in Bucks County, Pennsylvania]] |
|||
[[Category:Pharmaceutical companies of the United States]] |
|||
[[Category:Cannabis research]] |
|||
[[Category:American companies established in 2010]] |
|||
[[category:2010 in cannabis]] |
|||
Revision as of 01:52, 18 March 2021
Redirect to: